[go: up one dir, main page]

MX2013001677A - Formulaciones estables de linaclotida. - Google Patents

Formulaciones estables de linaclotida.

Info

Publication number
MX2013001677A
MX2013001677A MX2013001677A MX2013001677A MX2013001677A MX 2013001677 A MX2013001677 A MX 2013001677A MX 2013001677 A MX2013001677 A MX 2013001677A MX 2013001677 A MX2013001677 A MX 2013001677A MX 2013001677 A MX2013001677 A MX 2013001677A
Authority
MX
Mexico
Prior art keywords
linaclotide
stable formulations
compositions
processes
preparation
Prior art date
Application number
MX2013001677A
Other languages
English (en)
Other versions
MX348823B (es
Inventor
Brian Cali
Angelika Fretzen
Mahendra Dedhiya
Yun Mo
Original Assignee
Forest Lab Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Lab Holdings Ltd filed Critical Forest Lab Holdings Ltd
Publication of MX2013001677A publication Critical patent/MX2013001677A/es
Publication of MX348823B publication Critical patent/MX348823B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas estables que comprenden linaclotida o sales de la misma farmacéuticamente aceptable, así como también a varios métodos y procesos para la preparación y uso de las composiciones.
MX2013001677A 2010-08-11 2011-08-11 Formulaciones estables de linaclotida. MX348823B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37280410P 2010-08-11 2010-08-11
PCT/US2011/047434 WO2012021715A2 (en) 2010-08-11 2011-08-11 Stable formulations of linaclotide

Publications (2)

Publication Number Publication Date
MX2013001677A true MX2013001677A (es) 2013-07-22
MX348823B MX348823B (es) 2017-06-30

Family

ID=44630493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001677A MX348823B (es) 2010-08-11 2011-08-11 Formulaciones estables de linaclotida.

Country Status (17)

Country Link
US (7) US20140005128A1 (es)
EP (2) EP3626253B8 (es)
JP (2) JP5921545B2 (es)
CA (2) CA2808091C (es)
CY (1) CY1122853T1 (es)
DK (1) DK2603232T3 (es)
ES (2) ES2763404T3 (es)
HR (1) HRP20192207T1 (es)
HU (1) HUE046922T2 (es)
LT (1) LT2603232T (es)
MX (1) MX348823B (es)
PL (1) PL2603232T3 (es)
PT (1) PT2603232T (es)
RS (1) RS59978B1 (es)
SI (1) SI2603232T1 (es)
SM (1) SMT201900697T1 (es)
WO (1) WO2012021715A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626253B8 (en) 2010-08-11 2022-04-20 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
US20140018307A1 (en) * 2012-07-12 2014-01-16 Forest Laboratories Holdings Ltd. Linaclotide compositions
PT2968443T (pt) 2013-03-15 2021-12-28 Protagonist Therapeutics Inc Análogos de hepcidina e seus usos
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
US20160354509A1 (en) * 2014-02-10 2016-12-08 The Johns Hopkins University Devices for and methods of treatment of metabolic syndromes
SG10201810321PA (en) 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
ES2977537T3 (es) 2014-07-17 2024-08-26 Protagonist Therapeutics Inc Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
JP6385299B2 (ja) * 2015-03-03 2018-09-05 株式会社日立ハイテクノロジーズ 液体クロマトグラフ用遠紫外吸光度検出装置
WO2016197042A1 (en) * 2015-06-05 2016-12-08 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
MA47112A (fr) * 2016-12-21 2019-10-30 Ironwood Pharmaceuticals Inc Procédés de traitement du syndrome du côlon irritable avec des formulations à libération modifiée ou retardée de linaclotide
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN114206324A (zh) * 2019-06-10 2022-03-18 硬木药品公司 治疗与腹泻占主导的肠易激综合征相关的腹部疼痛
EP3997105A4 (en) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES
CN115279782A (zh) 2020-01-15 2022-11-01 詹森生物科技公司 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
IL294680A (en) 2020-01-15 2022-09-01 Janssen Biotech Inc Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases
IL302996B2 (en) 2020-11-20 2025-04-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
AU2022311814A1 (en) 2021-07-14 2024-02-29 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545931A (en) 1983-01-03 1985-10-08 Scripps Clinic And Research Foundation Synthetic heat-stable enterotoxin polypeptide of Escherichia coli
CH658973A5 (fr) 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
JPH0223849A (ja) * 1988-06-08 1990-01-26 Morishita Pharmaceut Co Ltd ペプチド含有栄養輸液組成物
EP0420964A4 (en) 1989-04-11 1991-09-25 Immunobiology Research Institute, Inc. Lyophilized peptide formulations
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6022858A (en) 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
WO1996010996A1 (en) 1993-07-21 1996-04-18 The University Of Kentucky Research Foundation A multicompartment hard capsule with control release properties
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5489670A (en) 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
ATE401394T1 (de) 1994-03-04 2008-08-15 Genentech Inc Verbesserte dnase flüssige lösungen
US5654278A (en) 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
WO1997033568A1 (en) 1996-03-12 1997-09-18 Novartis Ag Filled gelatin capsules having a reduced degree of cross-linking
CA2259403A1 (en) 1996-07-03 1998-01-08 Alza Corporation Non-aqueous protic peptide formulations
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
WO1998009645A1 (en) 1996-09-04 1998-03-12 Dott Research Laboratory Peptide-containing drug compositions for oral administration
US5705537A (en) 1997-02-24 1998-01-06 Armstrong World Industries, Inc. Phenolic foams having a low formaldehyde evolution
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
JP2002521322A (ja) 1998-07-23 2002-07-16 ノボ ノルディスク アクティーゼルスカブ 安定な医薬製剤の製造のための湿式顆粒化方法
CA2352389C (en) 1998-11-27 2009-01-20 Kanji Takada An oral formulation for gastrointestinal drug delivery
JP2003516316A (ja) 1999-10-06 2003-05-13 ファルマシア コーポレイション 腸癌阻止剤としてのウログアニリン
WO2001052937A1 (en) 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
KR20030017569A (ko) 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2002026248A1 (en) 2000-09-29 2002-04-04 Cognetix, Inc. Stable peptide formulations
WO2002055101A2 (en) 2000-12-21 2002-07-18 Inhale Therapeutic Syst Storage stable powder compositions of interleukin-4 receptor
JP2004521123A (ja) 2001-02-02 2004-07-15 ファルマシア・コーポレーション 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−２阻害薬の組合わせ
GB0104371D0 (en) 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
CA2905585C (en) 2001-03-29 2020-02-18 Synergy Pharmaceuticals, Inc. Guanylate cyclase receptor agonists for the treatment and/or prevention of cancer or polyps
AU2002355542A1 (en) 2001-08-09 2003-02-24 Doctor's Signature Sales And Marketing International Corp. ((Dba)) Life Force International Protonic formulation
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
CA2470313A1 (en) 2001-12-21 2003-07-10 Michael Bech Jensen Liquid composition of modified factor vii polypeptides
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
JPWO2004037293A1 (ja) 2002-10-22 2006-02-23 大日本住友製薬株式会社 安定化組成物
KR20050083841A (ko) 2002-10-29 2005-08-26 알자 코포레이션 안정화된 고체상태 폴리펩타이드 입자
PL377479A1 (pl) 2002-12-11 2006-02-06 Pfizer Products Inc. Kontrolowane uwalnianie substancji czynnej do środowiska o wysokiej zawartości tłuszczu
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE477268T1 (de) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004100968A2 (en) 2003-05-14 2004-11-25 Indus Biotech Pvt. Ltd. A synergistic composition for the treatment of diabetes mellitus
WO2004108152A1 (en) 2003-06-10 2004-12-16 Lg Life Sciences Ltd. Stable, aqueous solution of human erythropoietin, not containing serum albumin
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
DK1644021T3 (da) 2003-06-13 2012-10-29 Ironwood Pharmaceuticals Inc Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE202004020676U1 (de) 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
CN101094651B (zh) 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
EP1858352B1 (en) 2005-02-18 2013-06-05 Delante Health AS A composition comprising a powder containing microencapsulated polyunsaturated long-chain esterified fatty acids distributed in an effervescent base
EP1908482B1 (en) * 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US20090253634A1 (en) 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US7989418B2 (en) * 2005-10-28 2011-08-02 Nestec S.A. Methods for the use of branched chain amino acids
CA2642761A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
US20090305993A1 (en) 2006-02-24 2009-12-10 Ironwood Pharmaceuticals, Inc. Methods and composition for the treatment of gastrointestinal disorders
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
ES2532392T3 (es) 2006-07-10 2015-03-26 Pba3 Biomed Gmbh Péptidos antimicrobianos
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
PL2059260T3 (pl) 2006-08-31 2014-03-31 Novartis Ag Kompozycja farmaceutyczna obejmująca hGH do dostarczania doustnego
CA2666492C (en) 2006-10-20 2012-07-17 Douglas Rehder Stable polypeptide formulations
WO2008078189A2 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
EP2129683A4 (en) 2007-02-26 2011-01-05 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS
JP4906546B2 (ja) * 2007-03-15 2012-03-28 株式会社ヤクルト本社 レボホリナート含有水溶液製剤
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
NZ591713A (en) * 2008-08-15 2013-07-26 Ironwood Pharmaceuticals Inc Solid stable formulations of linaclotide for oral administration
WO2010027404A2 (en) 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Stable solid formulation of therapeutic polypeptides suitable for oral administration
US20120039949A1 (en) 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
JP2013501071A (ja) * 2009-08-06 2013-01-10 アイロンウッド ファーマシューティカルズ， インコーポレイテッド リナクロチドを含む処方物
MX2012001691A (es) 2009-08-12 2012-02-29 Forest Lab Holdings Ltd Composiciones de linaclotida que se desintegran oralmente.
EP3626253B8 (en) 2010-08-11 2022-04-20 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
WO2012155101A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (en) 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
DK2776055T3 (en) 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS

Also Published As

Publication number Publication date
EP3626253A2 (en) 2020-03-25
SMT201900697T1 (it) 2020-03-13
US20190209644A1 (en) 2019-07-11
DK2603232T3 (da) 2019-12-09
SI2603232T1 (sl) 2020-03-31
US10702576B2 (en) 2020-07-07
CA2808091A1 (en) 2012-02-16
CA2808091C (en) 2019-05-21
EP3626253B1 (en) 2022-03-16
HUE046922T2 (hu) 2020-03-30
US20220233635A1 (en) 2022-07-28
US20200030407A1 (en) 2020-01-30
EP3626253A3 (en) 2020-07-29
RS59978B1 (sr) 2020-03-31
EP3626253B8 (en) 2022-04-20
LT2603232T (lt) 2020-01-27
PT2603232T (pt) 2020-01-09
JP2016065105A (ja) 2016-04-28
CA3040415A1 (en) 2012-02-16
US20140005128A1 (en) 2014-01-02
ES2919136T3 (es) 2022-07-22
PL2603232T3 (pl) 2020-05-18
EP2603232A2 (en) 2013-06-19
HRP20192207T1 (hr) 2020-02-21
JP2013535505A (ja) 2013-09-12
CY1122853T1 (el) 2021-05-05
US20140378393A1 (en) 2014-12-25
ES2763404T3 (es) 2020-05-28
JP5921545B2 (ja) 2016-05-24
US20200009216A1 (en) 2020-01-09
WO2012021715A2 (en) 2012-02-16
WO2012021715A3 (en) 2012-05-18
EP2603232B1 (en) 2019-09-25
US20230346881A1 (en) 2023-11-02
US10675325B2 (en) 2020-06-09
MX348823B (es) 2017-06-30

Similar Documents

Publication Publication Date Title
MX348823B (es) Formulaciones estables de linaclotida.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
UA109010C2 (en) Morpholino pyrividines and their use in therapy
MX388963B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral
EP4414376A3 (en) Novel depsipeptide and uses thereof
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
EA201270741A1 (ru) Пероральные композиции и липофильные соли метилналтрексона
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
WO2011139255A3 (en) Pharmaceutical compositions comprising cefetamet
MX2014004742A (es) Nuevos agentes antibacterianos de fenicol.
IN2013MU01944A (es)

Legal Events

Date Code Title Description
FG Grant or registration